127 related articles for article (PubMed ID: 31113350)
1. Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation of the Therapeutic Efficacy In vitro.
Eskiler GG; Cecener G; Dikmen G; Egeli U; Tunca B
Curr Drug Deliv; 2019; 16(6):511-529. PubMed ID: 31113350
[TBL] [Abstract][Full Text] [Related]
2. Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
Guney Eskiler G; Cecener G; Egeli U; Tunca B
Pharm Res; 2018 Sep; 35(11):218. PubMed ID: 30255456
[TBL] [Abstract][Full Text] [Related]
3. BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile.
Guney Eskiler G; Cecener G; Egeli U; Tunca B
J Biochem Mol Toxicol; 2019 May; 33(5):e22286. PubMed ID: 30672063
[TBL] [Abstract][Full Text] [Related]
4. Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer.
Guney Eskiler G; Cecener G; Egeli U; Tunca B
J Cell Physiol; 2020 Sep; 235(9):6230-6245. PubMed ID: 32017076
[TBL] [Abstract][Full Text] [Related]
5. DR5 antibody conjugated lipid-based nanocarriers of gamma-secretase inhibitor for the treatment of triple negative breast cancer.
Pindiprolu SKSS; Krishnamurthy PT; Dev C; Chintamaneni PK
Chem Phys Lipids; 2021 Mar; 235():105033. PubMed ID: 33385372
[TBL] [Abstract][Full Text] [Related]
6. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies.
Wang S; Chen T; Chen R; Hu Y; Chen M; Wang Y
Int J Pharm; 2012 Jul; 430(1-2):238-46. PubMed ID: 22465546
[TBL] [Abstract][Full Text] [Related]
7. Development of Curcumin-Loaded Solid Lipid Nanoparticles Utilizing Glyceryl Monostearate as Single Lipid Using QbD Approach: Characterization and Evaluation of Anticancer Activity Against Human Breast Cancer Cell Line.
Bhatt H; Rompicharla SVK; Komanduri N; Aashma S; Paradkar S; Ghosh B; Biswas S
Curr Drug Deliv; 2018; 15(9):1271-1283. PubMed ID: 29732970
[TBL] [Abstract][Full Text] [Related]
8. The relationship between the efficacy of talazoparib and the functional toll-like receptors 3 and 9 in triple negative breast cancer.
Guney Eskiler G; Deveci Özkan A
Mol Immunol; 2022 Jan; 141():280-286. PubMed ID: 34906906
[TBL] [Abstract][Full Text] [Related]
9. Aloe-emodin loaded solid lipid nanoparticles: formulation design and in vitro anti-cancer study.
Chen R; Wang S; Zhang J; Chen M; Wang Y
Drug Deliv; 2015; 22(5):666-74. PubMed ID: 24512431
[TBL] [Abstract][Full Text] [Related]
10. Formulation-optimization of solid lipid nanocarrier system of STAT3 inhibitor to improve its activity in triple negative breast cancer cells.
Pindiprolu SKSS; Chintamaneni PK; Krishnamurthy PT; Ratna Sree Ganapathineedi K
Drug Dev Ind Pharm; 2019 Feb; 45(2):304-313. PubMed ID: 30348020
[TBL] [Abstract][Full Text] [Related]
11. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
12. The expression of APE1 in triple-negative breast cancer and its effect on drug sensitivity of olaparib.
Chen T; Liu C; Lu H; Yin M; Shao C; Hu X; Wu J; Wang Y
Tumour Biol; 2017 Oct; 39(10):1010428317713390. PubMed ID: 29064327
[TBL] [Abstract][Full Text] [Related]
13. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.
Wang B; Chu D; Feng Y; Shen Y; Aoyagi-Scharber M; Post LE
J Med Chem; 2016 Jan; 59(1):335-57. PubMed ID: 26652717
[TBL] [Abstract][Full Text] [Related]
14. The Interaction of PI3K Inhibition with Homologous Recombination Repair in Triple Negative Breast Cancer Cells.
Guney Eskiler G
J Pharm Pharm Sci; 2019; 22(1):599-611. PubMed ID: 31804921
[TBL] [Abstract][Full Text] [Related]
15. The augmented anticancer potential of AP9-cd loaded solid lipid nanoparticles in human leukemia Molt-4 cells and experimental tumor.
Bhushan S; Kakkar V; Pal HC; Mondhe DM; Kaur IP
Chem Biol Interact; 2016 Jan; 244():84-93. PubMed ID: 26620693
[TBL] [Abstract][Full Text] [Related]
16. Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).
Godugu C; Doddapaneni R; Singh M
Colloids Surf B Biointerfaces; 2017 May; 153():208-219. PubMed ID: 28249200
[TBL] [Abstract][Full Text] [Related]
17. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
18. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol loaded oxidized mesoporous carbon nanoparticles: A promising tool to treat triple negative breast cancer.
Fan C; Kong F; Shetti D; Zhang B; Yang Y; Wei K
Biochem Biophys Res Commun; 2019 Nov; 519(2):378-384. PubMed ID: 31519327
[TBL] [Abstract][Full Text] [Related]
20. Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine.
Nhukeaw T; Temboot P; Hansongnern K; Ratanaphan A
BMC Cancer; 2014 Feb; 14():73. PubMed ID: 24507701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
